ARA-290
ARA-290 (cibinetide) is a synthetic 11-amino-acid non-erythropoietic peptide modeled on EPO's helix B that activates the innate repair receptor, studied for small-fiber neuropathy and tissue repair; research protocols typically use 1.5 mg daily subcutaneously, 5 days on/2 off.
Best for
It has been studied primarily for small-fiber neuropathy and neuropathic pain (notably in sarcoidosis and type 2 diabetes), with broader research interest in its anti-inflammatory and tissue-repair signaling.
What to expect
In clinical research, neuropathic symptom and nerve-fiber changes were typically assessed over a roughly 28-day dosing course, with some symptom improvements reported during that period.
Pairs with
In research and anecdotal protocols it is sometimes discussed alongside other recovery- and repair-oriented peptides such as BPC-157 and TB-500, though controlled combination data are limited.
Published research has most often used subcutaneous administration, with controlled trials studying roughly 1-8 mg per day (commonly 4 mg) for about 28 days, while an earlier pilot used 2 mg intravenously three times weekly.
- How often
- 5 days on / 2 off
- When
- Morning
- Route
- Subcutaneous
- Vial & water
- 15 mg vial in 1 mL = 15 mg/mL · 1.5 mg = 10 units on a U-100 syringe
- Cycle
- 5 days on / 2 off; 8 weeks on, 8 weeks off
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide modeled on helix B of erythropoietin (EPO) — the region of the EPO molecule that engages tissue-protective signaling rather than red-blood-cell production.
ARA-290 is not FDA-approved; it remains an investigational research compound studied in Phase 2 trials and used as a research chemical, and is not an approved therapy for any condition.
Unlike EPO, it has been engineered to be non-erythropoietic: research describes it selectively activating the so-called innate repair receptor (IRR), a heterocomplex of the EPO receptor and the beta-common receptor (CD131) belonging to the type I cytokine receptor family. Through this pathway, studies have characterized anti-inflammatory and cytoprotective effects, including reductions in neuropathic pain and increases in small nerve fiber density (corneal and intraepidermal) in early-phase human research.
- Half-life
- ~20 min plasma (after 4 mg SC); biological effects outlast plasma levels
- Peak
- ~30-60 min post-SC
- Absorption
- Absorbed systemically after SC injection; rapid distribution
- Bioavailability
- SC/IV used; oral negligible (peptide degraded in GI tract); SC figure not well characterized
References3
- PubChem - Cibinetide (ARA 290) Compound Summary, CID 91810664 (sequence, molecular formula, CAS 1208243-50-8)
- Dahan A et al. - ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (Mol Med)
- Brines M et al. - ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes (Mol Med)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.